<DOC>
	<DOCNO>NCT02240966</DOCNO>
	<brief_summary>The purpose study investigate prevalence sign symptom hypogonadism three group testicular cancer survivor .</brief_summary>
	<brief_title>Symptoms Clinical Signs Hypogonadism Testicular Cancer Survivors</brief_title>
	<detailed_description>Recent study show metabolic syndrome common among testicular cancer . Patients low level testosterone appear high risk metabolic syndrome . A substantial number testicular cancer survivor might state `` compensate hypogonadism '' testosterone level low normal range due increase LH-drive pituitary gland . Whether specific group testicular cancer survivor increase risk cardio-vascular disease might benefit testosterone substitution yet clarify .</detailed_description>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>Earlier treatment testicular germ cell cancer No sign relapse &gt; 1 year since late treatment Testosterone &lt; 12 nmol/L luteinizing hormone &gt; 8 IE/L OR Testosterone &gt; 12 nmol/L LH &gt; 8 IE/L OR Testosterone LH within normal range Testosterone substitution</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Testicular Neoplasms</keyword>
	<keyword>Hypogonadism</keyword>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>Treatment related late effect</keyword>
</DOC>